<DOC>
	<DOCNO>NCT01025453</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , combination sorafenib temsirolimus thyroid cancer . Treatment guideline National Comprehensive Cancer Network include sorafenib treatment option thyroid cancer . Temsirolimus intravenous medication FDA approve type cancer . In laboratory study , addition temsirolimus sorafenib work well sorafenib alone .</brief_summary>
	<brief_title>Combination Temsirolimus Sorafenib Treatment Radioactive Iodine Refractory Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must histopathologically confirm MSKCC thyroid carcinoma follicular cell origin ( DTCFCO ) , include papillary , follicular , Hürthle cell histology , anaplastic along respective variant . Available pathology RAF mutational testing ( e.g. , paraffin block 510 unstained slide ) . It require mutational testing complete start clinical study . Patients must surgically inoperable and/or recurrent/metastatic disease . Patients must PET scan prior protocol start date least one FDGavid lesion remove surgically radiate ( unless progress RECIST criterion completion radiation therapy still FDGavid ) . FDGavidity define focus increase FDG uptake great normal activity SUV maximum level great equal 3 . PET scan do time prior start therapy , although recommend do within 3 month prior start therapy . Patients must measurable disease RECIST criterion , define least one lesion accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan ; perform ≤ 4 week protocol start date . Patients must progressive disease define least one follow occur previous treatment ( include RAI treatment ) : The presence new progressive lesion CT/MRI . New lesion bone scan PET scan . Rising thyroglobulin level ( document minimum three consecutive rise , interval &gt; 1 week determination ) . Prior RAI therapy allow &gt; 3 month prior initiation therapy protocol evidence progression ( define ) document interim . A diagnostic study use &lt; 10 mCi RAI consider RAI therapy . Patients may receive prior external beam radiation therapy index lesion ≥ 4 week prior initiation therapy protocol document progression RECIST criterion . Prior external beam radiation therapy nonindex lesion allow ≥ 4 week prior initiation therapy protocol . ECOG performance status ≤ 2 ( Karnofsky performance status ≥ 60 % ) . Patients must normal organ marrow function define : Absolute neutrophil count ≥1,500/mcL Platelets ≥100,000/mcL Total bilirubin ≤ 1.5 X institutional ULN AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 X institutional ULN Creatinine ≤ 1.5 X institutional ULN OR Creatinine clearance ≥ 60 mL/min/1.73 m2 patient creatinine level 1.5 X institutional ULN [ circumstance , either measure level base 24 hour urine collection , calculate level use Cockcroft Gault equation : ( 140 age year ) X ( weight kg ) X ( 0.85 female ) /72 X serum Cr may use ] . International normalized ratio ( INR ) ≤ 1.5 ( range INR , usually 2 3 , patient stable dose therapeutic warfarin ) . *ULN = upper limit normal **unless liver metastasis present AST/ALT &lt; 5 x ULN . Ability understand willingness sign write informed consent document . Age 21 year old old . Patients may receive investigational agent . Patients known history active intraparenchymal brain metastasis within previous 3 month . Serious nonhealing wound , ulcer , bone fracture . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day treatment . Patients report history clinically active diverticulosis diverticulitis prior 3 year . Patients clinically significant cardiovascular disease define follow : History CVA within past 6 month Myocardial infarction , CABG unstable angina within past 6 month New York Heart Association grade III great congestive heart failure Canadian Cardiovascular Class grade III great angina within past 6 month ( Appendices B &amp; C ) Clinically significant peripheral vascular disease within past 6 month Pulmonary embolism , DVT , thromboembolic event within past 6 month Uncontrolled coronary artery disease , angina , congestive heart failure , ventricular arrhythmia require acute medical management within past 6 month History myocardial infarct , cerebrovascular accident , transient ischemic event within past 6 month Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement . While use AngiotensinConverting Enzyme ( ACE ) inhibitor absolutely exclude , effort make see patient ACE inhibitor take medication switch another medication . Pregnant woman ineligible ; breastfeed discontinue mother treat study drug . The use agent inhibit induce CYP3A metabolism strictly prohibit , avoid possible . Potential CYP3A induce agent include carbamazepine , phenytoin , barbiturate , rifabutin , rifampicin , St. John 's Wort . Potential CYP3A inhibitor include protease inhibitor , antifungal , macrolide antibiotic , nefazodone , selective serotonin inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>thyroid</keyword>
	<keyword>follicular cell</keyword>
	<keyword>papillary cell</keyword>
	<keyword>Hurthle cell</keyword>
	<keyword>BAY 43-9006</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>09-148</keyword>
</DOC>